References

Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management

10.1002/ajh.26984 · 2023 · External reference

Emerging treatment options for patients with high-risk myelodysplastic syndrome

10.1177/2040620720955006 · 2020 · External reference

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

10.1182/blood-2019-124878 · 2019 · External reference

Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes

1993 · External reference

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

10.1016/s1470-2045(15)00038-8 · 2015 · External reference

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

10.1038/s41375-022-01613-1 · 2022 · External reference

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

10.1056/evidoa2200008 · 2022 · External reference

Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

2023 · External reference

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

10.1182/blood-2005-10-4149 · 2006 · External reference

lifelines: survival analysis in Python

10.21105/joss.01317 · 2019 · External reference

Unresolved reference

2011 · External reference

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

10.1200/jco.2002.04.117 · 2002 · External reference

Decitabine improves patient outcomes in myelodysplastic syndromes

10.1002/cncr.21792 · 2006 · External reference

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study

10.1182/blood.v110.11.817.817 · 2007 · External reference

Report of an international working group to standardize response criteria for myelodysplastic syndromes

2000 · External reference

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

10.1182/blood-2018-06-857102 · 2019 · External reference

Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses

10.1182/blood-2021-147558 · 2021 · External reference

Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium

10.1002/cam4.3608 · 2020 · External reference

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

10.1016/s1470-2045(16)00009-7 · 2016 · External reference

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

10.1182/bloodadvances.2019001101 · 2020 · External reference

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

10.1182/bloodadvances.2022007334 · 2022 · External reference

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

10.1182/blood-2020-142003 · 2020 · External reference

Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial

10.1182/blood.v126.23.1666.1666 · 2015 · External reference

Genetics of MDS

10.1182/blood-2018-10-844621 · 2019 · External reference